Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.39 USD | -6.71% | +2.05% | -57.18% |
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
Thomas Meyer
CEO | Chief Executive Officer | 56 | 03-03-31 |
Marcel Gremaud
DFI | Director of Finance/CFO | 66 | 21-10-31 |
Covadonga Pañeda
COO | Chief Operating Officer | 51 | - |
Samuel Wickline
CTO | Chief Tech/Sci/R&D Officer | 71 | 21-05-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Alain Munoz
BRD | Director/Board Member | 75 | 18-02-28 |
Mats Blom
BRD | Director/Board Member | 59 | 17-03-31 |
Thomas Meyer
CEO | Chief Executive Officer | 56 | 03-03-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 2,240,245 | 2,220,245 ( 99.11 %) | 0 | 99.11 % |
Company contact information
Altamira Therapeutics Ltd.
Clarendon House 2 Church Street
HM 11, Hamilton
+441 295 5950
http://www.altamiratherapeutics.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+19.03% | 125B | |
+14.24% | 108B | |
-4.78% | 24.57B | |
+3.23% | 22.82B | |
-10.44% | 18.19B | |
-41.74% | 16.54B | |
-13.32% | 16.5B | |
+2.76% | 13.39B | |
+28.68% | 11.1B |
- Stock Market
- Equities
- CYTO Stock
- CYTO Stock
- Company Altamira Therapeutics